The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation is a research paper published in Alzheimer s & Dementia (2025). On theSindex it has a DataRank of 0. It has been cited 6 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: U01 AG024904
National Institutes of Health
Grant: U01AG042791‐S1
U.S. Department of Defense
Grant: W81XWH‐12‐2‐0012
Foundation for the National Institutes of Health
Grant: U01AG052564
FNIH and Accelerating Medicines Partnership
Grant: R01AG046179
NIA NIH HHS
Grant: U19 AG032438
NIA NIH HHS
Grant: UF1 AG032438
Department of Defense
Grant: W81XWH-12-2-0012
NIA NIH HHS
Grant: U01 AG042791
NIA NIH HHS
Grant: R01 AG053267
the Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea
Grant: HI21C0066
NIH HHS
Grant: U01AG042791-S1
FNIH and Accelerating Medicines Partnership
Grant: R01AG053267-S1
NIA NIH HHS
Grant: R56 AG053267
National Institutes of Health
Grant: 3U01AG042791-02S1
DOMINANTLY INHERITED ALZHEIMER NETWORK TRIAL: AN OPPORTUNITY TO PREVENT DEMENTIA
National Institutes of Health
Grant: 5U19AG032438-03
DIAN Genetics Core
National Institutes of Health
Grant: 5R01AG053267-02
DIAN-TU: Next Generation Prevention Trial
National Institutes of Health
Grant: 1UL1TR002345-01
Washington University Institute of Clinical and Translational Sciences
Canadian Institutes of Health Research
Grant: unidentified
unidentified
National Institutes of Health
Grant: 3U01AG052564-02S2
Mapping the Human Connectome During Typical Aging
National Institutes of Health
Grant: 5R01AG046179-02
Dominantly Inherited Alzheimer's Network Trials Unit - Adaptive Prevention Trial
National Institutes of Health
Grant: 1U01AG024904-01
Alzheimers Disease Neuroimaging Initiative
Alzheimer's Association
GHR Foundation
German Center for Neurodegenerative Diseases (DZNE)
Korea Health Technology R&D
National Institute on Aging
Alzheimer's Association
Korea Dementia Research Center (KDRC)
National Institute of Biomedical Imaging and Bioengineering
Spanish Institute of Health Carlos III (ISCIII)
AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd
Eli Lilly and Company
Korea Health Industry Development Institute (KHIDI)
F. Hoffman-LaRoche Ltd.
Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research
NIBIB NIH HHS
The Dominantly Inherited Alzheimer Network
National Institute on Aging (NIA)
Raul Carrea Institute for Neurological Research (FLENI)
Alzheimer's Disease Neuroimaging Initiative
Avid Radiopharmaceuticals
Japan Agency for Medical Research and Development (AMED)
Alzheimer's Disease Neuroimaging Initiative
Fields of Study
MeSH Terms
Keywords